Data as of Aug 28
| -0.86 / -1.77%|
Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. The company has three product candidates in its clinical development pipeline: CO-1686, an oral epidermal growth factor receptor (EGFR), covalent inhibitor currently in Phase I/II development for the treatment of non-small cell lung cancer (NSCLC), in patients with initial activating EGFR mutations as well as the T790M primary resistance mutation; rucaparib, an oral, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor currently in Phase II development for ovarian cancer, which includes the global ARIEL2 (Assessment of Rucaparib in Ovarian Cancer Phase 2 Trial) study; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. Clovis Oncology was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
|Patrick J. Mahaffy||President, Chief Executive Officer & Director|
|Erle T. Mast||Chief Financial Officer, Secretary & Executive VP|
|Andrew R. Allen||Chief Medical Officer & EVP-Clinical Development|
|Gillian C. Ivers-Read||Chief Regulatory Officer & Executive VP|
|Steven L. Hoerter||Senior Vice President-Commercial Operations|